Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22,375.6%, EPS grew 48.2% and free cash flow fell 9.01%, each against the same quarter a year earlier.
Follow SEPN
Septerna, Inc. (SEPN) EV/Sales
As of 16 October 2026, Septerna, Inc. (SEPN) trades at a EV/Sales of 12.7×. Over the past ten years it has ranged from −276× (February 2025) to 654× (September 2025); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 18.3× | — |
| FY2024 | −116× | — |
| FY2023 | −87.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 11.5× | 14.01% |
| Mar 2026 | 10.1× | (45.06%) |
| Dec 2025 | 18.3× | 12.40% |
| Sep 2025 | 16.3× | (91.55%) |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | 1.6× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| NUVB Nuvation Bio Inc. compare | 6.7× |
| URGN Urogen Pharma compare | 9.7× |
| SEPN Septerna, Inc. | 12.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)